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Abstract
Background: Thoracic and cardiac irradiation increases the risk of pulmonary and cardiovascular disease. In addition,
radiation, often in combination with chemotherapy, can cause treatment-related pneumonitis. Previously, we showed
that the common marker for cardiac damage, troponin T, was not elevated by chemoradiation [Lung Cancer
62:351–355, 2008]. In this study, we explore whether dose-volume metrics and biomarkers for cardiac damage,
inflammation or angiogenesis could identify patients receiving thoracic radiation who would later have cardiac
or pulmonary complications.
Findings: To this end, we quantified cardiac biomarkers including c-reactive protein (cRP) as well as a panel of
angiogenic and inflammatory molecules in thirty patients who received radiation therapy to the thorax with or
without concurrent chemotherapy between May 2006 and May 2007. Serum was collected at baseline, 2 weeks
into radiation treatment and at the completion of radiation therapy. Heart and lung dosimetric parameters and
clinical risk factors were also examined, along with the monitoring of adverse pulmonary and cardiac events during
follow-up. Contrary to our hypothesis, there was no correlation between serum biomarker levels and cardiac radiation
dose. Similarly there was little association between lung dose-volume metrics and inflammatory or angiogenic
biomarkers. Furthermore, there was no correlation with serum biomarkers and adverse pulmonary or cardiovascular
events.
Conclusion: Based on these data, acute elevations in serum biomarkers of cardiac damage, inflammation or
angiogenesis should not be attributed to thoracic (chemo)radiation and elevations in such biomarkers of tissue
damage should be further evaluated.
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Findings
Background and motivation
The use of radiation to treat thoracic cancers can cause
treatment-related pneumonitis [1,2]. Similarly, cardiac
mortality increases in patients treated with radiation to
the chest [3-5]. To date, there are no validated biomarkers
to predict which patients will develop these side effects.
Because these patient populations tend to have extensive
co-morbidities, as well as a generally poor overall prog-
nosis, the harmful effects of thoracic irradiation do not
necessarily manifest clinically in many patients. However,
as survival continues to improve with better systemic ther-
apies and more effective radiation dose delivery, greater
focus is needed on the toxicities of thoracic radiotherapy.
Certain markers of inflammation (i.e.I n t e r l e u k i n - 6 )r i s e
in patients that go on to develop pneumonitis [6,7], how-
ever no study has evaluated a large panel of inflammatory
markers in individual patients. Furthermore, cardiac dis-
ease risk factors and symptoms overlap with those of
thoracic malignancies, which might mask early signs of
cardiac disease. Thus understanding how known bio-
markers of cardiac damage change during thoracic
radiotherapy might improve early detection of cardiac
compromise and may allow real-time modification of
radiation treatment to prevent further toxicity. Robust
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pulmonary pathologies would permit identification of
patients that require intense monitoring after radiation
treatment. These patients may potentially benefit from
earlier intervention to limit morbidity from radiation
induced pathologies.
Materials and methods
Serum samples were used from a cohort of patients previ-
ously published in [8] and summarized in Table 1. Briefly,
between May 2006 and May 2007, blood was collected
from 30 patients older than 18 years undergoing three-
dimensional conformal or intensity modulated radiation
therapy for a thoracic malignancy at Massachusetts General
Hospital. Patients were excluded if they had a history of
renal failure, hematocrit of less than 25% or previous thor-
acic radiotherapy. The study was approved by the Human
Research Committee of Partners Healthcare and written in-
formed consent was obtained from all patients. The average
serum storage time at −80°C was approximately 30 months,
which should maintain stability of the analytes including
cRP [9]. Each patient gave three samples: the first obtained
0–8 days prior to radiation therapy (Day 0), the second
following 8–10 fractions of radiation therapy (Day 10)
and the third at the end of radiation therapy (Day 42).
Cardiac and pulmonary dose-volume metrics were col-
lected from approved treatment plans by a radiation on-
cologist and entire heart and lungs were contoured on
radiation planning CT images. These data are summarized
in Table 2. Adverse cardiac and pulmonary events were di-
agnosed clinically and recorded.
Serum samples were analyzed using multiplex ELISA
from Mesoscale Discovery (Rockville, MD) and read on
a Mesocsale Discovery multiplex plate reader (Sector
Imager 2400). Each sample was run in duplicate on each
of 3 different multiplex ELISA arrays to include the fol-
lowing 18 analytes: c-reactive protein (cRP), serum amyloid
A (SAA), vascular cell adhesion molecule-1 (VCAM-1)
and intracellular adhesion molecule-1 (ICAM-1) (Vascular
Injury II kit; Mesoscale Discovery); interleukin (IL)-1β,
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, granulocyte-
macrophage colony-stimulating factor (GM-CSF) and tumor
necrosis factor-α (TNF-α) (Human Demonstration 10-Plex
Tissue Culture Kit; Mesoscale Discovery); basic fibroblast
growth factor (bFGF), placental growth factor (PlGF),
vascular endothelial growth factor (VEGF) and soluble
VEGF receptor-1 (sVEGFR-1) (Human Growth Factor
I Kit; Mesoscale Discovery).
Statistics
Principal component analysis (PCA) was performed to
reduce the number of variables characterizing dosimetry
in order to relate dosimetry to clinical events. Dosimetry
is described by the mean dose to the organ (i.e. heart or
lungs), the maximum dose to the organ and the percent
of the organ volume that received a dose of at least 5,
10, 15, 20, 30, 40, 50, 60 and 70 Gy. The first principal
component for 11 variables describing the dose to the
heart (Hmax, Hmean, HV5, HV10, HV15, HV20, HV30,
HV40, HV50, HV60, HV70) accounted for 61% of the
variance and inversely correlated with Hmean, HV5,
HV10, HV15, HV20 and HV30. The first principal compo-
nent for 11 variables describing the dose to the lungs
(Lmax, Lmean, LV5, LV10, LV15, LV20, LV30, LV40, LV50,
LV60, LV70) accounted for 52% of the variance and in-
v e r s e l yc o r r e l a t e dw i t hL m e a n ,L V 5 ,L V 1 0 ,L V 1 5 ,L V 2 0a n d
LV30. The correlation of dosimetric parameters with bioa-
nalyte protein levels, as well as the correlation between
cRP and SAA, was assessed using Kendall’s test with
Benjamini-Hochberg adjustments for multiple compari-
sons [10]. Based on our sample, we could detect Kendall’s
tau=0.34 with a power of 80% as statistically significant
with p< 0.05. Follow-up time was calculated using the
“reverse Kaplan-Meier” Method described by Schemper
and Smith [11]. To determine whether SAA values in
individual patients increased or decreased after 10 days
of radiation therapy, we used two criteria, as the baseline
Table 1 Patient characteristics (N= 30)
Characteristic N %
Male 17 57%
Female 13 43%
Diagnosis
Non-small cell lung cancer 18 60%
Small cell lung cancer 4 13%
Esophageal cancer 5 17%
Gastroesophageal junction cancer 2 7%
Thymic carcinoma 1 3%
Stage
I1 3 %
II 6 20%
III 13 43%
IV 5 17%
Limited small cell lung cancer 4 13%
Recurrent 1 3%
Prior resection
Yes 7 23%
No 23 77%
Induction chemotherapy
Yes 7 23%
No 23 77%
Concurrent chemotherapy
Yes 24 80%
No 6 20%
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of magnitude. A rise in SAA was determined by a 50% in-
crease in SAA from Day 0 to Day 10 as well as at least a
10 ng/ml increase in SAA. A decrease in SAA was deter-
mined by a 50% decrease in SAA from Day 0 to Day 10 as
well as at least a 10 ng/ml decrease in SAA. The same cri-
teria were used for cRP (using 10 μg/ml as the absolute
cut-off).
Results
Patient follow-up
Extending the average follow-up time to 3.4 years of the
patient cohort previously published [8], four out of the
30 patients developed pneumonitis after radiation and 12
of the 30 patients had cardiovascular events (myocardial
infarction, stroke, deep vein thrombosis, atrial fibrillation,
pulmonary embolism). Complications were recorded
solely based on a clinical diagnosis of the event.
Serum amyloid A (SAA) is elevated during radiation
therapy
Of the 18 analytes measured in patients receiving thoracic
radiation, only SAA—a protein associated with inflamma-
tory stimuli in a variety of settings [12,13]—showed a sta-
tistically significant change during the course of therapy.
SAA was elevated at Day 10 when taking the average of
all 30 patients (Figure 1A). However, individual patients
responded differently, with only 14 of the 30 patients
seeing increased levels of SAA at Day 10, while 8 pa-
tients had decreased levels and 8 patients showed no
difference (Figure 1B). The first principal component of
cardiac dosimetry was related to the average SAA levels
at Days 10 and 42. Similarly the mean radiation dose to
the heart correlated to the average SAA levels at the
same time points. Additionally, there was a significant
correlation between the percent volume of the heart
receiving 5 Gy and SAA levels at Days 10 and 42. How-
ever, this correlation with SAA levels was not found when
the percent volumes of the heart receiving 30 or 50 Gy
were tested.
Our data also showed a very weak association with levels
of cRP and cardiac dosimetry. 10 of the 30 patients
showed increases in cRP at Day 10, where only 4 patients
showed a decrease (Figures 1C,D). However, the magni-
tude of the increase in cRP was not large enough to detect
a statistically significant difference in this population. SAA
and cRP circulating protein levels positively correlated for
each individual time point (Kendall’s τ=0.71, 0.81 and
0.65 at Day 0, 10 and 42, respectively; p<0.05; Figure 2),
suggesting that they are mirroring the same underlying
biology. Furthermore, changes from Day 0 in SAA and
cRP circulating protein levels also positively correlate
(Kendall’s τ =0.64 and 0.63 for changes from day 0 to
day 10 and 42, respectively; p<0.05), suggesting that these
proteins rise and fall together and share a common re-
sponse mechanism. However from these data, SAA is a
more sensitive marker of radiation dose to the heart.
Even though there was an increase in SAA levels at Day
10, the levels trended back to baseline by the end of ther-
apy. Importantly, there was no correlation between pa-
tients with a rise in SAA and patients that eventually
had cardiovascular (or pulmonary) events. Thus the rise in
SAA was not predictive of a worse cardiovascular out-
come in this patient population. The other 16 analytes
measured did not show any correlation to cardiac dosim-
etry or the incidence of cardiac events (data not shown).
Inflammatory biomarkers are not correlated with
pneumonitis
It is known that the dose of radiation to the lungs is
correlated with pneumonitis [1]. The data from our
patient sample are consistent with this finding, as the
Table 2 Radiation dosimetry for the heart and lungs (n =30)
Cardiac Pulmonary
Parameter Median (range) Mean± SEM Median (range) Mean± SEM
Mean organ dose (Gy) 12.7 (0.6-41.0) 13.4±1.9 14.0 (3.3-34.3) 14.1±1.1
Maximum organ dose (Gy) 50.3 (1.6-73.4) 47.0±3.7 57.9 (42.7-80.5) 61.3±1.9
V5Gy (%) 63.4 (0–100) 55.7±6.8 61.3 (10.0-92.3) 58.1±4.2
V10Gy (%) 44.8 (0–100) 42.1±5.9 43.5 (7.9-87.1) 42.7±3.4
V15Gy (%) 31.5 (0–100) 33.2±5.3 34.5 (7.1-82.2) 34.0±2.8
V20Gy (%) 22.1 (0–100) 27.3±4.9 26.6 (5.1-78.0) 27.2±2.6
V30Gy (%) 11.9 (0–87.3) 16.9±3.7 14.3 (2.4-65.3) 16.9±2.2
V40Gy (%) 4.3 (0–65.0) 9.4±2.7 8.3 (0.3-42.2) 10.4±1.7
V50Gy (%) 0 (0–15) 2.0±0.6 3.0 (0–20.0) 4.5 ±0.9
V60Gy (%) 0 (0–3.2) 0.3±0.1 0 (0–8.1) 1.8 ±0.5
V70Gy (%) 0 (0–0.2) 0 0 (0–2.6) 0.2 ±0.1
VXGy (%) represents the percent of the total organ volume receiving a dose of at least X Gy.
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component of pulmonary dosimetry (p<0.05), with higher
doses corresponding to the incidence of pneumonitis.
However, none of the 18 serum biomarkers correlated
with lung dose-volume metrics (data not shown). Further-
more, there was no correlation between these biomarkers
and the incidence of pneumonitis. Thus, based on this pa-
tient sample, these biomarkers are not robust in predicting
pneumonitis in patients receiving thoracic radiation.
Conclusions
Although our patient sample is limited, no strong candi-
date serum biomarker emerged, which is a necessary con-
dition for patient stratification. Furthermore, individual
patient responses varied greatly (Figures 1B,D), making a
prediction in any particular patient even more challenging.
Nevertheless, small rises in cRP and SAA can be expected
when the heart receives radiation in the course of thoracic
radiotherapy, suggesting that they are not highly specific
biomarkers if a cardiac event is suspected in this setting.
These patients need alternative tests if cardiac events are
Figure 2 SAA and cRP are strongly correlated. The correlation of
SAA and cRP is independent of the timing the sample was taken
during the course of thoracic radiation therapy.
Figure 1 Serum amyloid A (SAA) rises in select patients during thoracic radiation. A) Average SAA rose during thoracic radiation and
returned to pre-treatment levels after radiotherapy was complete. B) Individual patients showed heterogeneity in the response of SAA during
thoracic radiation. Green lines show patients with increased levels of SAA after 10 days of radiotherapy. Red lines show patients with decreased
levels of SAA after 10 days of radiotherapy. Yellow lines show patients with no change in SAA after 10 days of radiotherapy. Dashed line shows
upper limit of normal values for SAA (2000 ng/ml). Data plotted on log scale to highlight the three orders of magnitude spread in the range of
values. C) c-Reactive Protein (cRP) showed an elevated trend during radiation but similarly returned to pre-treatment levels after radiotherapy.
D) Individual patients showed heterogeneity in the response of cRP during thoracic radiation. Green lines show patients with increased levels
of cRP after 10 days of radiotherapy. Red lines show patients with decreased levels of cRP after 10 days of radiotherapy. Yellow lines show patients with
no change in cRP after 10 days of radiotherapy. Dashed line shows upper limit of normal values for cRP (10 μg/ml). Data in (a) and (c) are
plotted as mean±SEM. *p<0.05.
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not elevate the biomarkers we measured. However, even
in this small study, the volume of lung and dose received
correlated to the development of pneumonitis, consistent
with the literature on this topic [2]. Thus, a predictive
serum biomarker for pneumonitis in the acute phase re-
mains elusive [7].
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